Autism Medication: A Parent's Map of the Evidence

Key takeaways

• No medicine treats autism itself. A medicine is chosen for one clear target, like dangerous aggression, ADHD symptoms, poor sleep, or a diagnosed anxiety disorder. 1 2
• Before any medicine, check what changed. Pain, constipation, dental problems, poor sleep, seizures, and side effects can all show up as behavior. 3
• Risperidone and aripiprazole are the only medicines the FDA has approved for irritability linked with autism in children and teens. Both can cause weight gain and need regular checks. 4 5
• Guanfacine extended-release has the best evidence of its group for hyperactivity in autistic children. It should not be stopped suddenly. 6 7
• Research says no to several popular ideas, including SSRIs for repetitive behavior in children, oxytocin nasal spray, and bumetanide. 8 9 10
• A calmer child who sleeps all day is not a success. Judge a medicine by safety and daily life, with a review date set before it starts. 2

Zoom

Start with the target, not the diagnosis

Autism is a lifelong difference in how a person senses, thinks, and communicates. No pill removes it. Flapping, rocking, little eye contact, and deep interests are not medicine targets when they cause no harm.

Medicines have not been shown to improve the core features of autism. 1 England’s national autism guideline advises against using antipsychotics or antidepressants for them. 2

A medicine makes sense when something is dangerous, painful, or blocking daily life. Examples are hitting that injures a sibling, head-banging that leaves bruises, or sleep so poor the whole family is falling apart. Recent expert guidance focuses medicine on conditions that often come along with autism, like ADHD, anxiety, and depression, after medical causes have been checked. 11

A good target is specific. “Irritable” is too vague. “Bites his arm more than five times a day and breaks the skin” gives everyone something to count.

Check what changed first

A sudden change in behavior needs a medical look before anyone adds a medicine. Autistic people may show pain through behavior instead of words. A primary care pathway from autism experts lists medical problems, communication barriers, stress, and other psychiatric conditions as things to check. 3 11

Common causes include:

• Constipation, reflux, tooth pain, ear or urinary infections, and menstrual pain
• Poor sleep, sleep apnea, or restless legs
• Seizures
• A new medicine, a dose change, or a medicine that was just stopped
• No reliable way to ask for help, a break, or “stop”
• Too much noise, crowding, or change at home or school

If you want more on this step, read our guide to missed conditions and what medication can target.

A map of the medicines

This table matches common targets with the options that have the most research. It is a starting point for a talk with your prescriber, not a plan to follow on your own.

The sections below explain the evidence for each row.

The two FDA-approved medicines

Risperidone and aripiprazole are approved for irritability linked with autism in children and teens. In these studies, irritability means aggression, deliberate self-injury, severe tantrums, and fast mood swings. 4 5 Neither medicine is approved to treat autism itself.

Risperidone. Its label lists trials in children and teens ages 5 to 17. 4 In the main trial, about 7 in 10 children on risperidone improved, compared with about 1 in 8 on placebo. 16 The label also pools short trials of children with several conditions. In those trials, about 1 in 3 children on risperidone gained at least 7% of their body weight. On placebo, it was about 1 in 14. Risperidone also often raises prolactin, a hormone that can affect breasts, periods, and sexual health. 4

Aripiprazole. It is approved for ages 6 to 17. 5 In its autism trials, about 1 in 4 children gained at least 7% of their body weight, compared with about 1 in 14 on placebo. Restlessness is a known side effect. The label also warns about strong urges, such as gambling or binge eating. 5

A 2024 review of 60 study reports rated the evidence for both medicines as high quality. The same review found that parent training also helped irritability, with moderate-quality evidence. 12 A 2025 Cochrane review was more cautious. It said these medicines may reduce irritability, and it noted that most of the trials were short. 32 In one trial, children who got risperidone plus parent training did better than children on risperidone alone, and they needed a slightly lower dose. 17

Medicines have not been shown to improve social connection or language. 1 For a closer look at these two options, read our guide to aggression and self-injury in autism.

Calmer, or just sleepy?

Wrap a cracked bell in wool and it goes quiet. The crack is still there. A medicine that only makes someone drowsy has not fixed what was wrong.

Before a medicine starts, agree on three things:

1. The target. One or two behaviors you can count.
2. The baseline. How often it happens now, how long it lasts, and whether anyone gets hurt.
3. The review date. When you will decide to continue, adjust, or stop.

For antipsychotic medicines like risperidone and aripiprazole in children and teens, England’s national guideline advises checking the effect and side effects after 3 to 4 weeks. It advises stopping if there is no sign of a meaningful response at 6 weeks. 2

Keep a simple weekly record at home. Write down the number of episodes, how long they lasted, any injury, the likely trigger, the night’s sleep, the dose, and any side effects. Change one thing at a time when you can. If three changes happen in one week, no one can tell which one helped.

Ask which checks the medicine needs. For risperidone and aripiprazole, this usually means weight, blood pressure, blood sugar, cholesterol, and a check for unusual movements. 4 5

Guanfacine and clonidine

These medicines turn down a brain chemical called noradrenaline. That can ease restlessness and impulsive actions. Their extended-release forms are approved for ADHD, not for autism. 7 18

In a trial of 62 autistic children with hyperactivity, guanfacine extended-release lowered hyperactivity scores by 44%, compared with 13% on placebo. Half the children on guanfacine were rated much improved, compared with fewer than 1 in 10 on placebo. Drowsiness was very common, and tiredness and lower appetite were also frequent. 6 A follow-up analysis found that defiant behavior also dropped. 19

Clonidine is also used. Its autism research is limited to a few very small studies. 20

Do not stop either medicine suddenly. Blood pressure can rebound to dangerous levels. Ask for a written plan to lower the dose slowly. 7 18

ADHD medicines in autistic children

More than 1 in 4 autistic people also have ADHD, based on a large review. 21 In a trial of methylphenidate in children with autism and hyperactivity, about half improved. About 1 in 5 stopped because of side effects, which is more than in children with ADHD alone. 13

Atomoxetine, a non-stimulant, lowered ADHD symptoms more than placebo in autistic children. 22 For more, read when autism and ADHD share a day.

What research says no to

Some ideas sound hopeful but did not hold up in careful trials.

• SSRIs for repetitive behavior in children. In a trial of 149 children, citalopram worked no better than placebo and caused more side effects, like increased energy, impulsiveness, and trouble sleeping. 15 A Cochrane review found no evidence of benefit in children and early signs of harm. 8 SSRIs can still make sense for a diagnosed anxiety disorder, depression, or OCD.
• Oxytocin nasal spray. A trial of 290 children and teens found no improvement in social or thinking skills. 9
• Bumetanide. Two late-stage trials in children and teens found no benefit, and both were stopped early. 10
• Chelation, hyperbaric oxygen, and secretin. A National Institutes of Health center says there is no scientific evidence that they help people with autism, and that misuse may be harmful. 23
• Cannabis products. A trial in 150 young people had mixed results. 24 These products are not part of routine care.

What about leucovorin? In March 2026, the FDA approved leucovorin tablets (Wellcovorin) for a rare genetic condition called cerebral folate transport deficiency. People must have a confirmed change in the FOLR1 gene. This is not an approval for autism. 25

New medicines in the news

You may see headlines about newer medicines. Here is where they stand as of September 2026:

• Brexpiprazole did no better than placebo in a late-stage trial for irritability in autism. 26
• Pimavanserin did no better than placebo in a trial of 237 children and teens, published in 2026. 27
• Cariprazine did better than placebo in one 2025 trial, reported so far only as a meeting summary. Its label says safety and effectiveness for irritability with autism have not been established. 28 29
• Lumateperone is still being tested. There are no results yet. 30

For now, none of these changes everyday care.

Teens and adults

Most autism medicine research was done in children. A small trial in 31 adults found that risperidone reduced aggression and repetitive behavior, but it did not improve social behavior or language. 31

Many young adults still take medicines started years ago. A yearly review is fair to ask for. Is the original target still there? Is the medicine still helping? Are side effects adding up?

Questions to ask before starting

• What exact behavior are we trying to change?
• What medical, sleep, and communication causes have we checked?
• How will we measure whether it works?
• Which side effects should we watch for, and which tests are needed?
• When will we decide to continue, change, or stop?
• What other support will happen at the same time?

When to call

Call the prescriber soon for new severe restlessness, stiffness, tremor, or strange face or body movements. Also call for fainting, heavy sleepiness, fast weight gain, extreme thirst, breast discharge, or missed periods. 4 5 Call, too, if aggression or mood gets worse.

Get emergency care for fever with severe muscle stiffness or confusion, collapse, a new or long seizure, serious injury, or anyone in immediate danger. 4

Frequently asked questions

Is there a medicine that treats autism itself? No. Medicines can treat specific targets, like dangerous aggression, ADHD symptoms, poor sleep, or a diagnosed anxiety disorder. None changes autism itself.

Which medicines are FDA-approved for autism? Risperidone and aripiprazole are approved for irritability linked with autism in children and teens. That means aggression, self-injury, severe tantrums, and fast mood swings. They are not approved to treat autism itself.

How long should a medicine trial last? It depends on the medicine. For risperidone and aripiprazole in young people, England’s national guideline advises a review at 3 to 4 weeks. It advises stopping if there is no meaningful response at 6 weeks. Set the review date before you start.

Can an SSRI help repetitive behaviors? Trials in children did not show reliable benefit, and side effects were more common. An SSRI may still help a diagnosed anxiety disorder, depression, or OCD.

Is leucovorin a treatment for autism? No. The FDA approved it in 2026 for a rare genetic condition that must be confirmed with testing. It is not approved for autism.

Can we stop a medicine on our own? Please don’t. Guanfacine and clonidine can cause a dangerous rise in blood pressure if stopped suddenly. Other medicines can cause withdrawal or a fast return of symptoms. Ask your prescriber for a plan.

Related reading on NP FADY

• Turn one knob, then wait: a safer autism medication plan
• Aggression and self-injury in autism
• Missed conditions and medication targets
• When autism and ADHD share a day
• Sleep in autism: what to try, what to check
• When anxiety narrows an autistic life

References

1. American Academy of Child and Adolescent Psychiatry, Autism Spectrum Disorder Work Group. Autism Spectrum Disorder: Parents’ Medication Guide. Washington, DC: AACAP; 2016. Source.

2. National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s: support and management (CG170), recommendations 1.3.2, 1.4.10, and 1.7.2. Published August 28, 2013; last updated June 14, 2021. Source.

3. McGuire K, Fung LK, Hagopian L, et al. Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care. Pediatrics. 2016;137(Suppl 2):S136–S148. DOI 10.1542/peds.2015-2851L. DOI.

4. Janssen Pharmaceuticals, Inc. RISPERDAL (risperidone) tablets, orally disintegrating tablets, and oral solution: prescribing information. DailyMed. Revised May 2026. Accessed September 16, 2026. Source.

5. Otsuka America Pharmaceutical, Inc. ABILIFY (aripiprazole) tablets: prescribing information. DailyMed. Revised January 2025. Accessed September 16, 2026. Source.

6. Scahill L, McCracken JT, King BH, et al. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal of Psychiatry. 2015;172:1197–1206. DOI 10.1176/appi.ajp.2015.15010055. DOI.

7. Takeda Pharmaceuticals America, Inc. INTUNIV (guanfacine) extended-release tablets: prescribing information. DailyMed. Revised June 2025. Accessed September 16, 2026. Source.

8. Williams K, Brignell A, Randall M, et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews. 2013;(8):CD004677. DOI 10.1002/14651858.CD004677.pub3. DOI.

9. Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine. 2021;385:1462–1473. DOI 10.1056/NEJMoa2103583. DOI.

10. Fuentes J, Parellada M, Georgoula C, et al. Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies. Autism Research. 2023;16:2021–2034. DOI 10.1002/aur.3005. DOI.

11. Manter MA, Birtwell KB, Bath J, et al. Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms. BMC Medicine. 2025;23:11. DOI 10.1186/s12916-024-03814-0. DOI.

12. Choi H, Kim JH, Yang HS, et al. Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment. Molecular Autism. 2024;15:7. DOI 10.1186/s13229-024-00585-6. DOI.

13. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders With Hyperactivity. Archives of General Psychiatry. 2005;62:1266–1274. DOI 10.1001/archpsyc.62.11.1266. DOI.

14. Williams Buckley A, Hirtz D, Oskoui M, et al. Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2020;94:392–404. DOI 10.1212/WNL.0000000000009033. DOI.

15. King BH, Hollander E, Sikich L, et al. Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior. Archives of General Psychiatry. 2009;66:583–590. DOI 10.1001/archgenpsychiatry.2009.30. DOI.

16. McCracken JT, McGough J, Shah B, et al.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in Children with Autism and Serious Behavioral Problems. New England Journal of Medicine. 2002;347:314–321. DOI 10.1056/NEJMoa013171. DOI.

17. Aman MG, McDougle CJ, Scahill L, et al. Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48:1143–1154. DOI 10.1097/CHI.0b013e3181bfd669. DOI.

18. Concordia Pharmaceuticals Inc. KAPVAY (clonidine hydrochloride) extended-release tablets: prescribing information. DailyMed. Revised December 2023. Accessed September 16, 2026. Source.

19. Politte LC, Scahill L, Figueroa J, et al. A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures. Neuropsychopharmacology. 2018;43:1772–1778. DOI 10.1038/s41386-018-0039-3. DOI.

20. Banas K, Sawchuk B. Clonidine as a Treatment of Behavioural Disturbances in Autism Spectrum Disorder: A Systematic Literature Review. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2020;29:110–120. Source.

21. Lai MC, Kassee C, Besney R, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6:819–829. DOI 10.1016/S2215-0366(19)30289-5. DOI.

22. Harfterkamp M, van de Loo-Neus G, Minderaa RB, et al. A Randomized Double-Blind Study of Atomoxetine Versus Placebo for Attention-Deficit/Hyperactivity Disorder Symptoms in Children With Autism Spectrum Disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2012;51:733–741. DOI 10.1016/j.jaac.2012.04.011. DOI.

23. National Center for Complementary and Integrative Health. Autism: In Depth. Bethesda, MD: NCCIH; updated January 2024. Accessed September 16, 2026. Source.

24. Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular Autism. 2021;12:6. DOI 10.1186/s13229-021-00420-2. DOI.

25. U.S. Food and Drug Administration. FDA approves first treatment for patients with cerebral folate transport deficiency. News release. March 10, 2026. Source.

26. Ward C, Childress A, Martinko K, et al. Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated With Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. 2025;35:194–201. DOI 10.1089/cap.2024.0118. DOI.

27. Bugarski-Kirola D, Hofbauer RK, Sameljak S, et al. Pimavanserin for irritability in children and adolescents with autism spectrum disorder: a phase 2 randomized trial. Journal of the American Academy of Child and Adolescent Psychiatry. Published online May 19, 2026. DOI 10.1016/j.jaac.2026.05.007. DOI.

28. Findling RL, Bozhdaraj D, Duffy WJ, et al. Cariprazine in the treatment of pediatric patients with irritability associated with ASD: a randomized controlled trial [meeting abstract]. Journal of the American Academy of Child and Adolescent Psychiatry. 2025;64(10 Suppl):S331. DOI 10.1016/j.jaac.2025.09.008. DOI.

29. Allergan, Inc. VRAYLAR (cariprazine) capsules: prescribing information. DailyMed. Revised December 2025. Accessed September 16, 2026. Source.

30. Johnson & Johnson Medical Connect. CAPLYTA: use in comorbid autism spectrum disorder. Updated August 12, 2026. Accessed September 16, 2026. Source.

31. McDougle CJ, Holmes JP, Carlson DC, et al. A Double-blind, Placebo-Controlled Study of Risperidone in Adults With Autistic Disorder and Other Pervasive Developmental Disorders. Archives of General Psychiatry. 1998;55:633–641. DOI 10.1001/archpsyc.55.7.633. DOI.

32. Meza N, Franco JVA, Sguassero Y, et al. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database of Systematic Reviews. 2025;5:CD014965. DOI 10.1002/14651858.CD014965.pub2. DOI.

---

This article is for education. It does not diagnose a condition, replace individual care, or promise services. Do not start, stop, or change any medicine without your prescribing clinician. Reading this does not create a clinician-patient relationship. Evidence checked September 16, 2026.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.